ClinicalTrials.gg
CompletedNCT05994378Updated Sep 15, 2025

To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects

A Phase 3 interventional study of SHR7280;Ganirelix Acetate Injection simulant and SHR7280 simulant; Ganirelix Acetate Injection in Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

This study is a multi-center, randomized, double-blind, positive drug-controlled, non-inferiority Phase III clinical trial. The study will enroll approximately 316 infertile female subjects undergoing controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment.

02

Conditions studied

  • Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Married infertile female subjects aged 20 to 39 years with indications for in vitro fertilization-embryo transfer (IVF-ET) or intracytoplasmic sperm injection (ICSI);
  2. (BMI) 18 \~ 28kg/m2 (both exclusive) and weight 45Kg \~ 75Kg (both inclusive);
  3. Regular menstrual cycle (24 \~ 35 days, both inclusive) for the last 3 months prior to screening;
  4. Anticipated normal ovarian response;
  5. Willingness of the subject to undergo fresh cycle transfer with one or two embryos at a time in the first IVF-ET cycle;
  6. Normal cervical cytology results (TCT) or with limited clinically significance within 1 year prior to screening or on the screening visit; or subjects with atypical squamous cells of undetermined significance (ASC-US) of TCT tested negative for high-risk types of human papillomavirus (HPV);
  7. of subjects and their spouses;

Exclusion criteria

Exclusion Criteria:

  1. Prior to screening, individuals underwent three or more IVF/ICSI-ET COH cycles without achieving clinical pregnancy;
  2. Previous IVF/ ICSI failure due to sperm/fertilization problems and no improvement in related medical condition;
  3. Subjects with more than 2 times of spontaneous abortion;
  4. Subjects at high risk of OHSS, judged by the investigator according to the Golan classification (e.g., those with moderate to severe OHSS during previous COH cycles, polycystic ovary syndrome (PCOS), or with previous cancelled COH cycles due to OHSS);
  5. Subjects with decreased ovarian reserve;
  6. TSH test result above or equal to 2.5 mIU/L for subjects with prior hypothyroidism or subclinical hypothyroidism on screening visit;
  7. Any pregnancy that occurred within 3 months prior to screening visit;
  8. Unexplained abnormal vaginal bleeding;
  9. Infectious disease screening indicates any of the following: positive for antibodies, positive for syphilis spirochete antibodies; positive for virus (HCV) antibodies and positive HCV-RNA test; positive for surface antigen (HBsAg) and HBV-DNA ≥ 1×103 kIU/L (or IU/mL);
  10. Use of fertility regulators within one month before ovarian stimulation, such as clomiphene citrate, letrozole, gonadotropins (Gn), metformin, hormonal drugs (including oral , estrogens, progestogens, etc.).
  11. Past medical history or gynecological ultrasound indicates conditions;
  12. and AST levels at the screening visit or the start of ovarian stimulation were more than twice the ;
  13. Positive serum β-hCG test results on the screening visit or the start day of ovarian stimulation;
  14. Blood or blood component donation within one month before screening, or a blood loss equivalent to at least 200 mL, or a blood transfusion within two months;
  15. Severe infection, severe trauma, or major surgery within six months before screening;
  16. Any disease or symptom that can affect systemic function and may affect the absorption, accumulation, metabolism, or excretion of the test drug (e.g., chronic intestinal diseases, Crohn's disease, ulcerative colitis).
  17. Major systemic diseases, endocrine or metabolic abnormalities;
  18. Thromboembolic diseases or a history of thromboembolic diseases;
  19. The subject or her spouse requires oocyte or sperm donation, or either or both of them carry a chromosomal abnormality deemed clinically significant by the researcher, or suffer from a known monogenic hereditary disease or a severe disease with genetic susceptibility requiring pre-implantation genetic testing (PGT);
  20. Smoking (more than 5 cigarettes or equivalent tobacco daily) or alcohol abuse (drinking ≥14 units of alcohol weekly: 1 unit = 360 mL beer, or 25 mL of 40% or higher spirits, or 1 glass of wine, 180 mL) within three months before screening;
  21. History of drug abuse or drug dependence;
  22. Allergic constitution or allergy to two or more foods or drugs, including a known allergy to any component of the test drug or non-test drug; or allergy to GnRH agonists or GnRH antagonists, recombinant or urinary FSH, hCG, progesterone drugs;
  23. Participation in any drug or medical device clinical trial within three months before screening, or still in the follow-up period of a clinical study before screening, or within the 5 half-lives of the test drug (whichever is longer);
  24. Malignant tumor or history of malignant tumor (except basal cell or squamous cell skin cancer, in situ cancer), or a high risk of malignant tumor onset/recurrence;
  25. Known history of severe mental illness, or inability to understand the purpose, methods, etc., of this clinical trial, or non-compliance with research procedures;
  26. Any other reasons deemed by the researcher as unsuitable for participation in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    Experimental group

    Drug: SHR7280;Ganirelix Acetate Injection simulant

  • Active comparator
    Control group

    Drug: SHR7280 simulant; Ganirelix Acetate Injection

Interventions

  • DrugSHR7280;Ganirelix Acetate Injection simulant

    SHR7280 200mg Q12h and Ganirelix Acetate Injection simulant 0.5mL qd;

  • SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;

06

What researchers measure

Primary outcomes

  1. Number of oocyte retrieved per COH cycle

    number of oocytes obtained after one COH cycle;

    Time frame: On oocyte retrieval 1 day

  2. Inhibition rate of premature LH surge

    premature LH surge is defined as: LH ≥ 10 IU/L and progesterone P ≥ 1 ng/mL (3.18 nmol/L);

    Time frame: the hCG injection 1 day

Secondary outcomes

  1. 2PN rate

    number of 2 pronuclei(2PN) oocytes/ number of oocytes retrieved or number of MII oocytes×100%;

    Time frame: 16-18 hours (h) after fertilization

  2. High quality embryo rate

    number of high-quality embryos/ cleavage number×100%;

    Time frame: 3 days after fertilization

  3. Chemical pregnancy rate

    number of pregnancy cycles/ number of transplantation cycles×100%;

    Time frame: on chemical pregnancy test 1 day

  4. Clinical pregnancy rate

    number of clinical pregnancy cycles/ number of transplantation cycles×100%;

    Time frame: on clinical pregnancy test 1 day

  5. Persistent pregnancy rate

    number of clinical pregnancy cycles/ number of transplantation cycles×100%;

    Time frame: on persistent pregnancy test 1 day

  6. Adverse drug events

    Time frame: Day 1 to persistent pregnancy test day/ or End-of-trial visit 1 day

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in May 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 16, 2023
StartActual
Aug 29, 2023
Primary completionActual
May 2, 2025
CompletionActual
May 2, 2025
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05994378
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Aug 29, 2023
Primary completion
May 2, 2025
Completion
May 2, 2025
Last update
Sep 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion